Sonic Healthcare Ltd. reported a stronger full-year profit, driven by robust revenue growth and improved underlying earnings across its medical diagnostics operations.
The Australian diagnostics giant warned investors that Swiss regulatory changes and extended integration timelines in the UK will weigh on EBITDA growth heading into fiscal 2027.
Shares in the company fell sharply in response to the cautious outlook, dropping nearly 10% on the ASX to trade at A$21.32 during the session.
Net profit after tax climbed to A$608 million, or 123 cents per share, compared with A$514 million, or 106.7 cents per share, recorded in the prior year.
Underlying net profit, which strips out one-time items, rose to A$621 million, or 125.6 cents per share, from A$531 million, or 110.3 cents per share a year earlier.
EBITDA grew 9% to A$1.882 billion from A$1.725 billion, while underlying EBITDA climbed 11% to A$1.933 billion from A$1.747 billion in the previous corresponding period.
Revenue surged 13% to A$10.867 billion for the full year, up from A$9.645 billion, reflecting broad-based growth across the company’s international diagnostics network.
The strong top-line performance underscores Sonic Healthcare’s continued expansion, though the market’s reaction suggests investors are more focused on the headwinds flagged for the year ahead.
Swiss regulatory changes represent a meaningful external pressure, as reimbursement environments in that market have historically been a stable contributor to the company’s European earnings.
UK integration delays add another layer of complexity, with extended timelines potentially pushing anticipated synergies and efficiency gains further out than the company had previously projected.
The combination of these two regional challenges has prompted caution among analysts and investors who had anticipated continued double-digit EBITDA growth momentum through FY27.
Despite the near-term concerns, Sonic Healthcare demonstrated confidence in its financial position by declaring a final dividend of A$0.63 per share, franked to 60%, payable on September 17 to shareholders on record as of September 3.
The dividend declaration signals that management remains committed to returning capital to shareholders even as it navigates a more challenging operating environment in key international markets.
Medical diagnostics companies globally continue to face shifting regulatory frameworks, and Sonic Healthcare’s experience in Switzerland highlights how quickly government policy changes can alter the earnings trajectory of established businesses.
